Novel recombinant antigen protein for japanese encephalitis, and use thereof
A recombinant Japanese encephalitis antigen protein, designed via structural stability analysis and mutations, addresses the ineffectiveness of existing vaccines against genotype G5, offering enhanced protection across all genotypes.
WO2026127647A1 Publication Date: 2026-06-18REPUBLIC OF KOREA (KOREA DISEASE CONTROL & PREVENTION AGENCY)
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- REPUBLIC OF KOREA (KOREA DISEASE CONTROL & PREVENTION AGENCY)
- Filing Date
- 2025-12-10
- Publication Date
- 2026-06-18
AI Technical Summary
⚠Technical Problem
Existing Japanese encephalitis vaccines are less effective against genotype G5 of the virus, providing only about 50% protection, while current vaccines are based on genotypes G3 and do not cover G5 effectively.
⚗Method used
Designing a recombinant Japanese encephalitis antigen protein through protein structural stability analysis and point mutations, specifically focusing on prM and E sequences of genotypes G1-G5, to enhance protection against all genotypes, including G5.
🎯Benefits of technology
The recombinant antigen protein demonstrates superior immunogenicity and protective ability against Japanese encephalitis virus genotypes G1 to G5, outperforming existing live vaccines in inducing immunity and challenge protection.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure 1 Figure 2
Abstract
The present invention relates to a novel recombinant antigen protein for Japanese encephalitis and, more specifically, to a recombinant antigen protein for Japanese encephalitis, designed through protein structural stability analysis and introduction of point mutations. It has been identified that a composition comprising the recombinant antigen protein for Japanese encephalitis, according to the present invention, exhibits immunogenicity and protective efficacy against challenge inoculation that are superior to those of an approved live-attenuated vaccine. In particular, it has been experimentally identified that the recombinant antigen protein for Japanese encephalitis, of the present invention, exhibits excellent protective efficacy against Japanese encephalitis virus G5 and other genotypes. Therefore, the recombinant antigen protein for Japanese encephalitis, of the present invention, can be variously used in the field of preventing infection by Japanese encephalitis virus G1 to G5.
Need to check novelty before this filing date? Find Prior Art